Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.EPS: As of FY2025 Q1, the actual value is USD -0.21.<h3>Segment Revenue</h3><ul><li>Consolidated Revenue: $104.4 million, an increase of 10.3% from $94.7 million compared to the prior year quarter.</li><li>Patient Services Revenue: $53.1 million, up 1.2% compared to Q1 2024.</li><li>Dispensary Revenue: $49.3 million, an increase of 24.2% compared to Q1 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $17.2 million, an increase of 44.1% compared to the prior year quarter.</li><li>Net Loss: $19.6 million compared to $19.9 million for the prior year quarter.</li><li>Adjusted EBITDA: - $5.1 million compared to - $10.9 million for the prior year quarter.</li><li>SG&amp;A Expenses: $25.4 million or 24.3% of revenue, compared with $28.5 million or 30.1% of revenue in Q1 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash and Cash Equivalents Used in Operating Activities: - $5.0 million for Q1 2025.</li><li>Free Cash Flow: - $4.0 million, compared to - $15.4 million in Q1 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Retail Pharmacy and Dispensary Revenue: $49.3 million, contributing over $9 million in gross profit in Q1.</li></ul><h3>Outlook / Guidance</h3><ul><li>The Oncology Institute reaffirms its full year 2025 guidance with expected revenue between $460 to $480 million, gross profit between $73 to $82 million, adjusted EBITDA between - $8 to - $17 million, and free cash flow between - $12 to - $21 million.</li><li>The company anticipates new capitation contracts in the first half of 2025 projected to add approximately $50 million in new revenue on an annualized basis.</li><li>TOI expects adjusted EBITDA of approximately - $4 to - $5 million in the second quarter of 2025 due to stabilization of contracts and initial lower encounter volumes.</li></ul>

Oncology Institute - CW22 | 8-K: FY2025 Q1 Revenue: USD 104.41 M